1CM
SGMT icon

1492 Capital Management’s Sagimet Biosciences SGMT Stock Holding History

1492 Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.4K Hold
15,000
– – 0.03% 129
2025
Q4 		$88.8K Hold
15,000
– – 0.03% 116
2025
Q3 		$103K Buy
+15,000
New +$122K 0.04% 112

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

1492 Capital Management's SGMT Position: Q1 2026 in Review

1492 Capital Management held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 15,000 shares worth $78.4K. The position accounts for 0.03% of the portfolio, ranked #129.

1492 Capital Management first reported a position in SGMT in Q3 2025 and has held it in 3 quarters since. The position peaked at $103K in Q3 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • 1492 Capital Management held 15,000 shares of Sagimet Biosciences worth $78.4K as of Q1 2026.
  • 1492 Capital Management left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up 0.03% of 1492 Capital Management's portfolio in Q1 2026, its #129 holding.
  • 1492 Capital Management first reported a position in Sagimet Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 1492 Capital Management's Sagimet Biosciences position peaked at $103K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.